Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (181-190 of 192) with videos related to

Pageof 20
Sort By:
The European Respiratory Journal|April 1, 2022
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trialKohei Otsubo, Junji Kishimoto, Masahiko Ando, et al.
JCI Insight|April 7, 2022
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancerKentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Frontiers in Immunology|July 30, 2024
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter studyNaoya Nishioka, Hayato Kawachi, Tadaaki Yamada, et al.
Scientific Reports|March 6, 2023
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancerDaichi Fujimoto, Satoru Miura, Keisuke Tomii, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
American Journal of Respiratory and Critical Care Medicine|July 3, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trialDaichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Histologic transformation of epidermal growth factor receptor-mutated lung cancerDaichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world settingRyosuke Tsugitomi, Kento Takagi, Go Saito, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 20

Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
The European Respiratory Journal|April 1, 2022
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trialKohei Otsubo, Junji Kishimoto, Masahiko Ando, et al.
JCI Insight|April 7, 2022
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancerKentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Frontiers in Immunology|July 30, 2024
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter studyNaoya Nishioka, Hayato Kawachi, Tadaaki Yamada, et al.
Scientific Reports|March 6, 2023
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancerDaichi Fujimoto, Satoru Miura, Keisuke Tomii, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
American Journal of Respiratory and Critical Care Medicine|July 3, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trialDaichi Fujimoto, Mitsuhiro Abe, Kenta Murotani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Histologic transformation of epidermal growth factor receptor-mutated lung cancerDaichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world settingRyosuke Tsugitomi, Kento Takagi, Go Saito, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 20